Dicerna Pharmaceuticals, Inc.

Eli Lilly has seen tremendous revenue growth and become one of the most highly valued pharmaceutical companies in the world based on its GLP-1/GIP agonist tirzepatide – Mounjaro for type 2 diabetes an

Novartis has been heralding its slimmed-down, more-focused pipeline to analysts for which much of the credit goes to Shreeram Aradhye, who after a spell in US biotech returned to his roots with the

With the oft-cited patent cliff looming, big pharma companies are still looking to replenish pipelines. For many, partnering represents an important avenue to do so with its more limited financial ris

While most biotechs struggle amid a prolonged funding winter, one group is doing just fine. We are not talking about artificial intelligence. Several start-ups working on nucleic acid-based therapies